Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Johnson & Johnson stock price, quote, forecast and news

JNJ
US4781601046
853260

Price

166.99
Today +/-
+1.32
Today %
+0.88 %
P

Johnson & Johnson stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Johnson & Johnson stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Johnson & Johnson stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Johnson & Johnson stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Johnson & Johnson's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Johnson & Johnson Stock Price History

DateJohnson & Johnson Price
9/16/2024166.99 undefined
9/13/2024165.52 undefined
9/12/2024164.64 undefined
9/11/2024164.82 undefined
9/10/2024167.38 undefined
9/9/2024166.61 undefined
9/6/2024164.38 undefined
9/5/2024164.99 undefined
9/4/2024167.36 undefined
9/3/2024167.16 undefined
8/30/2024165.86 undefined
8/29/2024164.23 undefined
8/28/2024163.92 undefined
8/27/2024162.95 undefined
8/26/2024164.61 undefined
8/23/2024164.13 undefined
8/22/2024162.35 undefined
8/21/2024161.43 undefined
8/20/2024160.16 undefined
8/19/2024159.63 undefined

Johnson & Johnson Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Johnson & Johnson, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Johnson & Johnson from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Johnson & Johnson’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Johnson & Johnson. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Johnson & Johnson’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Johnson & Johnson’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Johnson & Johnson’s growth potential.

Johnson & Johnson Revenue, EBIT and net profit per share

DateJohnson & Johnson RevenueJohnson & Johnson EBITJohnson & Johnson Net Income
2029e112.77 B undefined0 undefined34.88 B undefined
2028e107.43 B undefined36.73 B undefined31.96 B undefined
2027e101.5 B undefined34.26 B undefined29.65 B undefined
2026e95.27 B undefined31.26 B undefined27.31 B undefined
2025e92.01 B undefined29.87 B undefined26.06 B undefined
2024e89.14 B undefined27.93 B undefined24.38 B undefined
202385.16 B undefined24.25 B undefined35.15 B undefined
202279.99 B undefined23.29 B undefined17.94 B undefined
202178.74 B undefined20.63 B undefined20.88 B undefined
202082.58 B undefined20.52 B undefined14.71 B undefined
201982.06 B undefined18.6 B undefined15.12 B undefined
201881.58 B undefined20.22 B undefined15.3 B undefined
201776.45 B undefined19.39 B undefined1.3 B undefined
201671.89 B undefined20.93 B undefined16.54 B undefined
201570.07 B undefined20.47 B undefined15.41 B undefined
201474.33 B undefined21.21 B undefined16.32 B undefined
201371.31 B undefined17.07 B undefined13.83 B undefined
201267.22 B undefined17.14 B undefined10.85 B undefined
201165.03 B undefined13.41 B undefined9.67 B undefined
201061.59 B undefined17.18 B undefined13.33 B undefined
200961.9 B undefined17.19 B undefined12.27 B undefined
200863.75 B undefined17.18 B undefined12.95 B undefined
200761.1 B undefined14.68 B undefined10.58 B undefined
200653.32 B undefined14.38 B undefined11.05 B undefined
200550.51 B undefined13.05 B undefined10.06 B undefined
200447.35 B undefined12.34 B undefined8.18 B undefined

Johnson & Johnson Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
5.996.156.467.068.079.079.8411.3312.5713.9914.315.9219.0721.9823.1224.428.0129.1732.3236.341.8647.3550.5153.3261.163.7561.961.5965.0367.2271.3174.3370.0771.8976.4581.5882.0682.5878.7479.9985.1689.1492.0195.27101.5107.43112.77
-2.655.059.1414.4412.398.4315.1610.9411.252.2711.2919.8015.295.165.5414.794.1610.7812.3215.3313.106.695.5614.574.34-2.90-0.505.593.376.084.23-5.732.596.346.710.590.64-4.651.596.464.673.223.556.545.854.96
58.6959.7959.7262.5263.1963.5664.4865.0866.2166.0565.9666.3966.9467.5768.4668.6669.6669.3070.3571.2270.9171.5472.2771.7670.9570.9670.2069.4968.6967.7869.6369.4069.3869.9066.8466.9266.5465.7070.2869.2569.18------
3.523.683.864.415.15.776.347.378.329.249.4310.5712.7714.8515.8316.7519.5120.2222.7425.8529.6933.8736.538.2743.3445.2443.4542.844.6745.5749.6551.5948.6250.2551.154.654.654.2655.3455.3958.92000000
0.780.820.960.381.241.461.61.772.012.162.382.753.384.124.625.075.876.657.79.3811.2612.3413.0514.3814.6817.1817.1917.1813.4117.1417.0721.2120.4720.9319.3920.2218.620.5220.6323.2924.2527.9329.8731.2634.2636.730
13.0013.2514.825.3315.3516.0516.2715.6015.9515.4416.6417.2717.7118.7520.0020.7720.9422.7923.8325.8526.8926.0625.8226.9724.0326.9627.7727.8920.6225.5023.9428.5429.2129.1125.3624.7822.6724.8426.2029.1128.4831.3432.4632.8233.7534.18-
0.490.520.620.340.850.991.11.171.270.981.791.962.422.963.113.14.274.955.676.67.28.1810.0611.0510.5812.9512.2713.339.6710.8513.8316.3215.4116.541.315.315.1214.7120.8817.9435.1524.3826.0627.3129.6531.9634.88
-6.1119.77-45.67149.8517.0011.106.098.73-23.0782.809.8023.3022.334.97-0.1337.7915.9114.4416.399.1013.6622.989.87-4.3222.44-5.278.71-27.4612.2127.4418.02-5.607.34-92.141,076.69-1.16-2.6841.89-14.0795.94-30.646.874.828.567.799.13
-----------------------------------------------
-----------------------------------------------
3.143.13.032.982.892.862.82.82.92.882.842.842.893.053.073.083.13.13.13.053.012.9932.962.912.842.792.792.782.812.882.862.812.792.752.732.682.672.672.662.56000000
-----------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Johnson & Johnson Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Johnson & Johnson is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                                 
0.450.460.861.040.880.780.691.230.961.010.571.051.362.523.072.984.16.767.977.489.5212.8816.144.089.3212.8119.4327.6632.2621.0929.2133.0938.3841.9118.319.6919.2925.1931.6123.5222.93
0.840.880.970.870.971.161.341.551.811.912.162.692.93.373.433.94.364.64.635.46.576.837.018.719.449.729.659.7710.5811.3111.7110.9910.7311.713.4914.114.4813.5815.2816.1614.87
00000000000000000000000000000000000000000
10.950.961.021.171.281.361.561.721.771.742.192.282.542.552.953.162.912.993.33.593.743.964.895.115.055.185.386.297.57.888.188.058.148.778.69.029.3410.3912.4811.18
0.20.250.250.380.420.440.530.680.690.960.941.241.41.51.862.082.012.432.883.093.313.864.375.296.086.85.294.55.196.227.617.053.053.282.543.652.493.133.73.134.51
2.482.543.033.33.443.663.925.025.185.655.427.177.949.9310.9211.9113.6316.6918.4719.272327.3231.4822.9829.9534.3839.5447.3154.3246.1256.4159.3160.2165.0343.0946.0345.2751.2460.9855.2953.5
1.681.741.861.952.322.592.983.43.854.334.635.165.25.966.126.777.147.417.728.719.8510.4410.8313.0414.1914.3714.7614.5514.7416.116.7116.1315.9115.9117.0117.0418.6219.7719.8620.920.9
0.180.160.150.160.140.190.250.260.40.560.60.350.340.960.750.760.810.660.970.120.080.050.020.02000000000000.511.151.481.880.584.47
00000000000000000000000000000000000000000
000.080.390.620.610.70.710.740.720.932.42.953.113.267.367.573.74.514.596.155.986.1915.3514.6413.9816.3216.7218.1428.7527.9527.2225.7626.8853.2347.6147.6453.446.3948.3334.18
000000000000000003.844.574.655.395.865.9913.3414.1213.7214.8615.2916.1422.4222.821.8321.6322.8131.9130.4533.6436.3935.2545.2336.56
0.160.150.130.210.270.340.350.660.931.331.31.391.451.661.772.161.861.952.253.213.83.674.365.838.068.479.29.0410.317.968.826.639.910.5812.0811.3111.4112.6217.6617.0517.96
2.022.052.222.713.353.724.295.025.916.937.459.39.9411.6911.917.0517.3817.5520.0221.2925.272627.3847.5851.0150.5455.1455.659.3375.2376.2871.8173.276.18114.22106.92112.45123.66121.04132.08114.06
4.54.595.266.016.797.388.2110.0411.0912.5812.8616.4717.8721.6222.8228.9631.0234.2538.4940.5648.2653.3258.8670.5680.9584.9194.68102.91113.64121.35132.68131.12133.41141.21157.3152.95157.73174.89182.02187.38167.56
                                                                                 
0.280.280.340.370.190.380.380.390.390.770.770.771.541.541.542.181.543.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.123.12
272278248186292211219227392405295302-643623810706-35-30-25-18-110000000000000000000
2.733.033.423.524.094.575.235.866.636.657.749.049.7411.2512.5913.8716.1818.1123.0726.5730.535.2242.3149.2955.2863.3870.3177.7781.2585.9989.4997.25103.88110.55101.79106.22110.66113.89123.06128.35153.84
-242-347-283-16376-22-914134-238-422-115148-179-434-377-440-461-530-842-590-515-755-2,118-693-4,980-3,028-3,555-6,080-6,005-2,966-10,979-13,769-15,312-13,431-15,222-15,891-15,243-13,055-12,940-12,526
000000000000000000000000025-3024448195106257604411232001-3-27-1
3.033.233.733.914.655.155.826.617.447.598.389.9911.3612.9714.0715.6717.9820.7425.6328.8233.0237.8244.6850.2957.7161.5470.3777.3678.7483.389.7589.6493.8398.7791.7194.1197.89101.77113.12118.5144.44
0.310.30.450.520.570.660.630.840.940.920.911.211.61.771.811.942.082.122.843.624.975.234.325.696.917.55.545.625.735.836.277.636.676.927.317.548.549.5111.0611.79.63
0.260.330.330.510.50.630.630.860.931.321.31.882.242.372.643.533.493.324.156.46.916.718.1710.249.29.439.259.5712.6913.7913.3113.3313.7117.4720.0823.9528.9729.2929.230.21
0.140.220.220.270.360.080.110.070.160.190.120.330.220.240.230.210.210.320.540.710.941.510.940.720.220.420.440.580.851.060.770.50.750.971.851.322.271.391.112.132.99
00000000000000000000000000000000000000.831.6411.221.98
0.210.20.231.010.360.520.570.880.681.031.170.90.320.870.722.751.811.490.572.121.140.280.674.582.463.736.327.626.664.684.853.6474.683.912.31.21.82.131.551.47
0.931.051.232.311.791.891.942.642.713.473.54.324.395.255.398.427.597.268.0411.4513.4513.9312.6419.1619.8420.8521.7323.0722.8124.2625.6825.0927.7526.2930.5431.2335.9642.4945.2355.846.28
0.220.250.210.240.811.241.251.591.511.591.492.542.112.292.052.653.393.162.222.022.962.572.022.017.078.128.229.1612.9711.4913.3315.1212.8622.4430.6827.6826.4932.6429.9926.8925.88
0.10.090.120.030.0200000.090.120.130.160.170.180.580.290.260.490.640.780.40.211.321.491.431.421.451.83.143.993.152.562.918.377.515.967.217.496.373.19
0.220.250.270.490.550.590.680.690.921.851.881.992.182.482.552.72.853.183.53.754.214.615.298.749.231212.7212.6518.9817.6315.6418.0119.119.1527.5626.7829.8429.2725.321.5123.43
0.540.60.60.761.381.831.932.282.433.543.494.674.444.944.785.936.526.66.216.417.957.587.5212.0817.821.5522.3623.2633.7532.2632.9636.2834.5144.566.6161.9762.2969.1262.7754.7752.5
1.471.641.823.073.173.723.874.925.1476.998.998.8310.1910.1614.3514.1113.8514.2617.8621.3921.520.1531.2437.6442.444.0946.3356.5656.5258.6361.3762.2670.7997.1493.298.26111.62108110.5798.78
4.54.885.556.987.818.879.6911.5312.5814.5915.3718.9820.1923.1624.2330.0232.0934.5939.8846.6854.4159.3264.8381.5395.34103.95114.46123.69135.3139.82148.38151.01156.1169.56188.86187.32196.15213.38221.12229.07243.22
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Johnson & Johnson provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Johnson & Johnson's financial health and stability.

Assets

Johnson & Johnson's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Johnson & Johnson must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Johnson & Johnson after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Johnson & Johnson's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (B)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.520.620.350.850.991.11.171.41.11.832.062.482.983.043.114.274.955.676.67.28.1810.0611.0510.5812.9512.2713.339.6710.5113.8316.3215.4116.541.315.315.1214.7120.8817.9435.15
0.230.260.290.360.40.420.480.50.570.630.740.871.031.111.321.511.591.611.661.872.122.092.182.782.832.772.943.163.674.13.93.753.755.646.937.017.237.396.977.49
-0.020.04-0.19-0.06-0.01-0.01-0.04-0.02-0.01-0.02-0.07-0.06-0-0.13-0.3-0.03-0.13-0.11-0.07-0.72-0.68-0.24-1.17-1.760.02-0.440.36-0.84-0.04-0.610.44-0.27-0.342.41-1.02-2.48-1.14-2.08-1.66-4.19
0.090.060.21-0.04-0.48-0.240.08-0.27-0.03-0.210.310.19-0.010.080.610.140.381.49-0.191.330.93-0.990.981.23-1.731.28-0.871.49-1.97-0.94-0.831.63-1.7711.2403.872.69-4.24-4.012.51
000.4600000.090.610.010.010.020.020.090.360.020.110.20.180.920.530.871.22.91.521.311.241.433.891.76-0.33-0.071.471.431.970.881.052.593.1-17
00.030.040.090.090.130.190.130.130.170.140.140.130.130.20.240.220.190.140.210.220.150.140.310.530.530.490.580.620.60.60.620.730.961.0510.90.991.923.6
00.270.20.330.510.430.520.640.580.690.641.111.251.491.341.461.652.092.013.153.883.434.254.14.072.362.442.972.513.163.542.872.843.314.574.194.624.775.228.57
0.80.991.111.110.91.271.681.692.252.243.053.494.014.185.15.926.98.868.1810.611.0911.814.2515.0214.9716.5716.3914.315.417.4118.7119.5718.7721.0622.223.4223.5423.4121.1922.79
-366-372-464-547-692-794-854-1,021-1,144-999-974-1,302-1,422-1,457-1,610-1,822-1,689-1,731-2,099-2,262-2,175-2,632-2,666-2,942-3,066-2,365-2,384-2,893-2,934-3,595-3,714-3,463-3,226-3,279-3,670-3,498-3,347-3,652-4,009-4,543
-293-573-616-575-738-935-1,125-1,182-1,337-1,169-2,680-1,215-2,255-1,535-6,198-3,093-2,665-4,093-2,197-4,526-2,347-279-20,291-5,912-4,187-7,598-7,854-4,612-4,510-5,103-12,305-7,735-4,761-14,868-3,167-6,194-20,825-8,683-12,371878
0.07-0.2-0.15-0.03-0.05-0.14-0.27-0.16-0.19-0.17-1.710.09-0.83-0.08-4.59-1.27-0.98-2.36-0.1-2.26-0.172.35-17.63-2.97-1.12-5.23-5.47-1.72-1.58-1.51-8.59-4.27-1.54-11.590.5-2.7-17.48-5.03-8.365.42
0000000000000000000000000000000000000000
0.05-0.030.81-0.150.620.050.6-0.210.470.010.74-0.70.36-0.382.26-0.25-0.12-1.151.58-0.25-1.160.293.753.022.732.482.42.98-3.672.030.851.387.886.75-3.95-2.887.1-0.997.45-2.73
-30632-764-170-552-98-130-142-653-485-116-202-211-419-691-619-586-2,056-6,148-872-700-943-5,587-4,045-5,165-1,248-1,571-1,279-10,199-889-5,581-4,285-7,790-5,296-4,919-5,792-2,107-2,420-4,706281
-481-229-245-595-258-421-63-860-775-1,385-104-1,727-828-1,932262-2,347-2,425-5,251-6,953-3,863-5,106-4,443-6,109-5,698-7,464-4,092-4,980-4,452-20,562-6,091-12,499-11,136-8,551-7,673-18,510-18,015-6,120-14,047-8,871-15,825
00-41000-10000-250000000000000000000-83560-57-15-188-148575-62739565-1,602
-220-233-245-278-327-373-436-513-587-659-727-827-974-1,137-1,305-1,479-1,724-2,047-2,381-2,746-3,251-3,793-4,267-4,670-5,024-5,327-5,804-6,156-6,614-7,286-7,768-8,173-8,621-8,943-9,494-9,917-10,481-11,032-11,682-11,770
0.020.210.29-0.01-0.12-0.080.53-0.360.1-0.350.30.560.910.65-0.810.411.77-0.52-0.862.483.836.85-11.973.6935.043.555.19-9.636.02-6.4-0.795.24-1.150.28-0.8-3.320.5-0.367.73
4376136505642054808266731,1011,2452,0762,1912,5922,7253,4944,0985,2147,1336,0778,3338,9149,16711,58212,08011,90614,20614,00111,40512,46213,81914,99616,10615,54117,77718,53119,91820,18919,75817,18518,248
0000000000000000000000000000000000000000

Johnson & Johnson stock margins

The Johnson & Johnson margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Johnson & Johnson. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Johnson & Johnson.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Johnson & Johnson's sales revenue. A higher gross margin percentage indicates that the Johnson & Johnson retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Johnson & Johnson's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Johnson & Johnson's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Johnson & Johnson's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Johnson & Johnson. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Johnson & Johnson's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Johnson & Johnson Margin History

Johnson & Johnson Gross marginJohnson & Johnson Profit marginJohnson & Johnson EBIT marginJohnson & Johnson Profit margin
2029e69.18 %0 %30.93 %
2028e69.18 %34.18 %29.75 %
2027e69.18 %33.75 %29.21 %
2026e69.18 %32.82 %28.67 %
2025e69.18 %32.46 %28.32 %
2024e69.18 %31.34 %27.35 %
202369.18 %28.48 %41.28 %
202269.25 %29.11 %22.43 %
202170.28 %26.2 %26.52 %
202065.7 %24.84 %17.82 %
201966.54 %22.67 %18.42 %
201866.92 %24.78 %18.75 %
201766.84 %25.36 %1.7 %
201669.9 %29.11 %23.01 %
201569.38 %29.21 %21.99 %
201469.4 %28.54 %21.96 %
201369.63 %23.94 %19.4 %
201267.78 %25.5 %16.14 %
201168.69 %20.62 %14.87 %
201069.49 %27.89 %21.65 %
200970.2 %27.77 %19.82 %
200870.96 %26.96 %20.31 %
200770.95 %24.03 %17.31 %
200671.76 %26.97 %20.73 %
200572.27 %25.82 %19.92 %
200471.54 %26.06 %17.28 %

Johnson & Johnson Stock Sales Revenue, EBIT, Earnings per Share

The Johnson & Johnson earnings per share therefore indicates how much revenue Johnson & Johnson has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Johnson & Johnson earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Johnson & Johnson's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Johnson & Johnson’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Johnson & Johnson's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Johnson & Johnson Revenue, EBIT and net profit per share

DateJohnson & Johnson Sales per ShareJohnson & Johnson EBIT per shareJohnson & Johnson Earnings per Share
2029e46.84 undefined0 undefined14.49 undefined
2028e44.63 undefined0 undefined13.28 undefined
2027e42.16 undefined0 undefined12.32 undefined
2026e39.58 undefined0 undefined11.35 undefined
2025e38.22 undefined0 undefined10.82 undefined
2024e37.03 undefined0 undefined10.13 undefined
202333.26 undefined9.47 undefined13.73 undefined
202230.03 undefined8.74 undefined6.73 undefined
202129.45 undefined7.72 undefined7.81 undefined
202030.92 undefined7.68 undefined5.51 undefined
201930.57 undefined6.93 undefined5.63 undefined
201829.9 undefined7.41 undefined5.61 undefined
201727.85 undefined7.06 undefined0.47 undefined
201625.78 undefined7.5 undefined5.93 undefined
201524.91 undefined7.28 undefined5.48 undefined
201425.95 undefined7.41 undefined5.7 undefined
201324.79 undefined5.93 undefined4.81 undefined
201223.9 undefined6.1 undefined3.86 undefined
201123.43 undefined4.83 undefined3.49 undefined
201022.08 undefined6.16 undefined4.78 undefined
200922.19 undefined6.16 undefined4.4 undefined
200822.48 undefined6.06 undefined4.57 undefined
200720.99 undefined5.04 undefined3.63 undefined
200618.01 undefined4.86 undefined3.73 undefined
200516.82 undefined4.34 undefined3.35 undefined
200415.82 undefined4.12 undefined2.73 undefined

Johnson & Johnson business model

Johnson & Johnson is an American company that was founded in 1886 by the brothers Robert, James, and Edward Johnson. The company is headquartered in New Brunswick, New Jersey, USA and is now an internationally operating company with more than 130,000 employees worldwide. The history of Johnson & Johnson began with the production of medical bandages. In 1887, the first self-adhesive wound plaster was invented and patented. In the following years, the product range was significantly expanded and now includes a wide range of health products. This includes pharmaceuticals, medical devices, hygiene products, personal care products, and baby products. The business model of Johnson & Johnson is to improve the lives of people worldwide. The company places great importance on innovation, quality, and sustainability. With its long-standing experience and expertise in the healthcare industry, Johnson & Johnson is able to understand the needs of customers and offer products tailored to their specific needs. Johnson & Johnson is now active in three main business areas: Consumer Health, Medical Devices and Diagnostics, and Pharmaceuticals. Within these business areas, there are a variety of brands and products that are among the most well-known in the world. The Consumer Health division of Johnson & Johnson is focused on the production of health and personal care products for consumers. Some well-known brands in this area include Listerine, Johnson's Baby, Neutrogena, and Nicorette. The company offers a wide range of products, from cold and allergy medications to skincare products and toothpastes. Medical Devices and Diagnostics is another major business area of Johnson & Johnson. The company is a leading provider of medical devices and diagnostic products worldwide. Products in this area include surgical systems, implantable devices, diagnostic tests, and imaging devices. Well-known brands in this area include Ethicon, Depuy Synthes, and Cordis. Pharmaceuticals is the third major business area of Johnson & Johnson. The company develops and produces innovative pharmaceuticals for the treatment of diseases such as cancer, diabetes, heart disease, and neurological disorders. Some well-known brands in this area include Remicade, Invega, and Zytiga. Johnson & Johnson is also known for its commitment to sustainability and corporate social responsibility. The company is committed to having a positive impact on the environment and the communities in which it operates. For example, Johnson & Johnson aims to reduce its CO2 emissions by 60% by 2030. Overall, Johnson & Johnson is a leading healthcare company focused on providing innovative and high-quality products that improve the lives of people worldwide. With a wide range of brands and products in various business areas, the company is well positioned to continue to be successful in the future. Johnson & Johnson is one of the most popular companies on Eulerpool.com.

Johnson & Johnson SWOT Analysis

Strengths

Johnson & Johnson (J&J) possesses several key strengths that contribute to its success in the market. Firstly, the company has a diversified product portfolio spanning various sectors such as healthcare, pharmaceuticals, and consumer goods. This diversification allows J&J to leverage its brand equity and penetrate multiple markets effectively.

Secondly, J&J has a strong brand reputation built on trust and reliability. The company is known for its high-quality products, which have earned consumer loyalty over the years. This positive brand perception gives J&J a competitive edge and enhances customer trust, leading to continued business growth.

Additionally, J&J has a vast global presence, operating in multiple countries around the world. This global reach provides the company with access to diverse markets and a broad customer base. It enables J&J to adapt to changing market dynamics and explore new growth opportunities.

Weaknesses

Despite its strengths, J&J also faces some notable weaknesses. One of the main weaknesses is its dependence on external suppliers for raw materials and components. Any disruption in the supply chain could impact production and result in delays or shortages of J&J products.

Furthermore, J&J has experienced product recalls and legal issues in the past, which have affected its reputation and financial performance. These incidents highlight a need for stricter quality control measures and regulatory compliance within the organization.

Opportunities

J&J has several opportunities to capitalize on in the market. One notable opportunity is the growing demand for healthcare and pharmaceutical products, driven by an aging population and increasing healthcare needs globally. J&J can leverage its expertise and expand its product offerings to cater to these emerging market needs.

Additionally, advancements in technology and digitalization present opportunities for J&J to enhance its product innovation and delivery channels. Embracing digital platforms and integrating technology in its operations can help the company stay competitive and meet changing customer preferences.

Threats

J&J needs to be aware of several potential threats that may impact its business. One significant threat is increasing competition from both established players and new entrants in the healthcare and pharmaceutical industries. This competition may affect market share and profitability.

Moreover, evolving regulations and policies in the healthcare sector pose a threat to J&J's operations. Compliance with stricter regulations can increase costs and restrict product development and distribution processes.

Additionally, the current global economic environment and geopolitical uncertainties may impact consumer spending patterns, which could result in lower demand for J&J products.

Johnson & Johnson Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Johnson & Johnson Revenue by Segment

Segmente202320232022202120192018
Xarelto----2.31 B USD2.48 B USD
Stelara----6.36 B USD5.16 B USD
Remicade----4.38 B USD5.33 B USD
GENERAL----4.48 B USD4.56 B USD
ADVANCED----4.1 B USD4 B USD
OTC----4.44 B USD2.48 B USD
CONTACT LENSES/OTHER----3.39 B USD3.3 B USD
Beauty----4.59 B USD1.98 B USD
SPINE & OTHER----3.2 B USD3.27 B USD
ZYTIGA----2.8 B USD3.5 B USD
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA----3.33 B USD2.93 B USD
IMBRUVICA----3.41 B USD2.62 B USD
TRAUMA----2.72 B USD2.7 B USD
DARZALEX----3 B USD2.03 B USD
Simponi/Simponi Aria----2.19 B USD2.08 B USD
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA----2.11 B USD1.96 B USD
OTHER NEUROSCIENCE----1.61 B USD1.75 B USD
Baby Care----1.68 B USD1.44 B USD
KNEES----1.48 B USD1.5 B USD
HIPS----1.44 B USD1.42 B USD
OPSUMIT----1.33 B USD1.22 B USD
SURGICAL----1.23 B USD1.25 B USD
Oral Care----1.53 B USD918 M USD
SPECIALTY----926 M USD1.34 B USD
Women's Health----986 M USD1.04 B USD
VELCADE----751 M USD1.12 B USD
PROCRIT/EPREX----790 M USD988 M USD
EDURANT/rilpivirine----861 M USD816 M USD
INVOKANA/INVOKAMET----735 M USD881 M USD
Other----1.35 B USD149 M USD
UPTRAVI----819 M USD663 M USD
RISPERDAL CONSTA----688 M USD737 M USD
CONCERTA/Methylphenidate----696 M USD663 M USD
Other Oncology----739 M USD590 M USD
Tremfya----1.01 B USD-
Other Infectious Diseases----441 M USD533 M USD
Wound Care and Other----671 M USD239 M USD
TRACLEER----341 M USD546 M USD
Tremfaya-----544 M USD
Other Immunology----10 M USD10 M USD
Stelara9.72 B USD10.86 B USD9.13 B USD7.71 B USD--
DARZALEX7.98 B USD9.74 B USD6.02 B USD4.19 B USD--
GENERAL5.12 B USD5.37 B USD5.19 B USD4.39 B USD--
ADVANCED4.57 B USD4.67 B USD4.62 B USD3.84 B USD--
OTC6.03 B USD-5.23 B USD4.82 B USD--
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA4.14 B USD4.12 B USD4.02 B USD3.65 B USD--
IMBRUVICA3.78 B USD3.26 B USD4.37 B USD4.13 B USD--
CONTACT LENSES/OTHER3.54 B USD3.7 B USD3.44 B USD2.99 B USD--
Skin health/Beauty4.35 B USD-4.54 B USD4.45 B USD--
TRAUMA2.87 B USD2.98 B USD2.89 B USD2.61 B USD--
Remicade2.34 B USD1.84 B USD3.19 B USD3.75 B USD--
Tremfya2.67 B USD3.15 B USD2.13 B USD1.35 B USD--
Simponi/Simponi Aria2.18 B USD2.2 B USD2.28 B USD2.24 B USD--
SPINE,SPORTS & OTHER2.84 B USD2.95 B USD2.89 B USD---
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA1.94 B USD1.85 B USD2.08 B USD2.18 B USD--
XARELTO2.47 B USD2.37 B USD2.44 B USD---
OPSUMIT1.78 B USD1.97 B USD1.82 B USD1.64 B USD--
OTHER NEUROSCIENCE1.62 B USD1.55 B USD1.73 B USD1.63 B USD--
HIPS1.51 B USD1.56 B USD1.49 B USD1.28 B USD--
COVID-192.18 B USD1.12 B USD2.39 B USD---
ERLEADA1.88 B USD2.39 B USD1.29 B USD---
KNEES1.36 B USD1.46 B USD1.33 B USD1.17 B USD--
UPTRAVI1.32 B USD1.58 B USD1.24 B USD1.09 B USD--
ZYTIGA/abiraterone acetate1.77 B USD887 M USD2.3 B USD---
SURGICAL1.31 B USD1.37 B USD1.25 B USD925 M USD--
Oral Care1.51 B USD-1.65 B USD1.64 B USD--
ELECTROPHYSIOLOGY-4.69 B USD----
Baby Care1.46 B USD-1.57 B USD1.52 B USD--
Other966 M USD1.31 B USD981 M USD1.19 B USD--
EDURANT/rilpivirine1.01 B USD1.15 B USD994 M USD964 M USD--
Women's Health904 M USD-917 M USD901 M USD--
CONCERTA/Methylphenidate644 M USD783 M USD667 M USD622 M USD--
SPINE & OTHER---2.7 B USD--
ZYTIGA---2.47 B USD--
Other Oncology571 M USD879 M USD568 M USD413 M USD--
RISPERDAL CONSTA485 M USD689 M USD592 M USD642 M USD--
Xarelto---2.35 B USD--
Wound Care and Other700 M USD-739 M USD720 M USD--
INVOKANA/INVOKAMET448 M USD-563 M USD795 M USD--
Other Infectious Diseases318 M USD297 M USD399 M USD427 M USD--
Abiomed-1.31 B USD----
PROCRIT/EPREX--479 M USD552 M USD--
Erleada---760 M USD--
CARVYKTI-500 M USD----
VELCADE---408 M USD--
Other Interventional Solutions-356 M USD----
Other Immunology17 M USD11 M USD24 M USD11 M USD--
Pharmaceutical52.56 B USD-52.08 B USD45.57 B USD--
Medical Devices----25.96 B USD4.55 B USD
Consumer----13.9 B USD8.09 B USD
Medical Devices27.43 B USD-27.06 B USD22.96 B USD--
Pharmaceutical----42.2 B USD2.57 B USD
Consumer Health14.95 B USD-14.64 B USD---
Consumer---14.05 B USD--
Innovative Medicine-54.76 B USD----
MedTech-30.4 B USD----

Johnson & Johnson Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Johnson & Johnson Revenue by Segment

DateAsia-Pacific, AfricaEuropeOperating SegmentsOther CountriesU.S. PlansUnited StatesWestern Hemisphere excluding U.SWestern Hemisphere, excluding U.S.
2023---46.36 B USD48.58 B USD---
2023---38.72 B USD46.44 B USD---
2022---46.62 B USD47.16 B USD---
2021---39.45 B USD43.13 B USD---
2019---39.96 B USD42.1 B USD---
2018---39.7 B USD-41.88 B USD--
201712.58 B USD15.77 B USD71.89 B USD--37.81 B USD5.73 B USD-
201713.42 B USD17.13 B USD76.45 B USD--39.86 B USD6.04 B USD-
201612.35 B USD16 B USD70.07 B USD--35.69 B USD-6.05 B USD
201413.44 B USD18.95 B USD74.33 B USD--34.78 B USD-7.16 B USD
201313.38 B USD18.6 B USD71.31 B USD--31.91 B USD-7.42 B USD
201212.58 B USD17.13 B USD65.03 B USD--28.91 B USD-6.42 B USD
201213.24 B USD16.95 B USD67.22 B USD--29.83 B USD-7.21 B USD

Johnson & Johnson Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Johnson & Johnson historical P/E ratio, EBIT, and P/S ratio.

Johnson & Johnson shares outstanding

The number of shares was Johnson & Johnson in 2023 — This indicates how many shares 2.56 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Johnson & Johnson earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Johnson & Johnson's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Johnson & Johnson’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Johnson & Johnson's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Johnson & Johnson Stock splits

In Johnson & Johnson's history, there have been no stock splits.

Johnson & Johnson dividend history and estimates

In 2023, Johnson & Johnson paid a dividend amounting to 4.7 USD. Dividend means that Johnson & Johnson distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Johnson & Johnson provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Johnson & Johnson’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Johnson & Johnson's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Johnson & Johnson Dividend History

DateJohnson & Johnson Dividend
2029e5.11 undefined
2028e5.1 undefined
2027e5.11 undefined
2026e5.11 undefined
2025e5.1 undefined
2024e5.12 undefined
20234.7 undefined
20224.45 undefined
20214.19 undefined
20203.98 undefined
20193.75 undefined
20183.54 undefined
20173.32 undefined
20163.15 undefined
20152.95 undefined
20142.76 undefined
20132.59 undefined
20122.4 undefined
20112.25 undefined
20102.11 undefined
20091.93 undefined
20081.8 undefined
20071.62 undefined
20061.46 undefined
20051.28 undefined
20041.09 undefined

Johnson & Johnson dividend payout ratio

In 2023, Johnson & Johnson had a payout ratio of 64.07%. The payout ratio indicates the percentage of the company's profits that Johnson & Johnson distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Johnson & Johnson represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Johnson & Johnson could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Johnson & Johnson's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Johnson & Johnson Payout Ratio History

DateJohnson & Johnson Payout ratio
2029e63 %
2028e63.21 %
2027e62.73 %
2026e63.07 %
2025e63.83 %
2024e61.3 %
202364.07 %
202266.12 %
202153.72 %
202072.36 %
201966.61 %
201863.1 %
2017706.38 %
201653.12 %
201553.83 %
201448.42 %
201353.85 %
201262.18 %
201164.47 %
201044.14 %
200943.86 %
200839.28 %
200744.63 %
200639.01 %
200538.06 %
200439.96 %
Unfortunately, there are currently no price targets and forecasts available for Johnson & Johnson.

Johnson & Johnson latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20242.73 2.82  (3.37 %)2024 Q2
3/31/20242.66 2.71  (1.74 %)2024 Q1
12/31/20232.3 2.29  (-0.59 %)2023 Q4
9/30/20232.54 2.66  (4.68 %)2023 Q3
6/30/20232.64 2.8  (5.96 %)2023 Q2
3/31/20232.53 2.68  (5.95 %)2023 Q1
12/31/20222.25 2.35  (4.36 %)2022 Q4
9/30/20222.5 2.55  (2.14 %)2022 Q3
6/30/20222.56 2.59  (1.14 %)2022 Q2
3/31/20222.59 2.67  (3.1 %)2022 Q1
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Johnson & Johnson stock

Eulerpool World ESG Rating (EESG©)

80/ 100

🌱 Environment

88

👫 Social

94

🏛️ Governance

59

Environment

Scope 1 - Direct Emissions
384,622
Scope 2 - Indirect emissions from purchased energy
606,096
Scope 3 - Indirect emissions within the value chain
17,944,555
Total CO₂ emissions
990,718
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
❌
Pesticides
—
Palm Oil
❌
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees49
Percentage of women in management—
Percentage of Asian employees13.8
Share of Asian management19.6
Percentage of Hispanic/Latino employees11.2
Hispano/Latino Management share8
Percentage of Black employees8.3
Black Management Share6.6
Percentage of white employees64.1
White Management Share63.9
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic❌

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law✅

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Johnson & Johnson list of shareholders

%
Name
Stocks
Change
Date
9.48891 % The Vanguard Group, Inc.228,420,89585,83612/31/2023
5.52102 % State Street Global Advisors (US)132,904,2951,954,15712/31/2023
5.10613 % BlackRock Institutional Trust Company, N.A.122,916,8452,647,84012/31/2023
2.12928 % Geode Capital Management, L.L.C.51,256,7854,214,76112/31/2023
1.31584 % State Farm Insurance Companies31,675,492012/31/2023
1.20410 % Capital International Investors28,985,676-54312/31/2023
1.07912 % Norges Bank Investment Management (NBIM)25,977,042-116,35612/31/2023
0.99781 % Wellington Management Company, LLP24,019,7253,391,65712/31/2023
0.91824 % Legal & General Investment Management Ltd.22,104,2214,021,88312/31/2023
0.91576 % Morgan Stanley Smith Barney LLC22,044,601-537,74212/31/2023
1
2
3
4
5
...
10

Johnson & Johnson Executives and Management Board

Mr. Joaquin Duato60
Johnson & Johnson Chairman of the Board, Chief Executive Officer (since 2016)
Compensation 13.1 M
Mr. Joseph Wolk56
Johnson & Johnson Chief Financial Officer, Executive Vice President
Compensation 8.82 M
Ms. Jennifer Taubert59
Johnson & Johnson Executive Vice President, Worldwide Chairman, Pharmaceuticals
Compensation 8.78 M
Dr. Peter Fasolo60
Johnson & Johnson Chief Human Resource Officer, Executive Vice President
Compensation 3.62 M
Ms. Anne Mulcahy70
Johnson & Johnson Lead Independent Director
Compensation 410,000
1
2
3
4
...
5

Johnson & Johnson Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SourceBio International Stock
SourceBio International
SupplierCustomer--0,11-0,27-0,34-0,08-
Softec SpA Stock
Softec SpA
SupplierCustomer--0,110,12-0,45-0,160,22
Apria, Inc. Stock
Apria, Inc.
SupplierCustomer-0,050,830,25-0,06-
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Stock
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
SupplierCustomer0,860,51----
Emergent BioSolutions Inc. Stock
Emergent BioSolutions Inc.
SupplierCustomer0,850,14-0,38-0,27-0,10-0,65
Berkshire Hathaway B Stock
Berkshire Hathaway B
SupplierCustomer0,850,160,700,790,630,89
Glatfelter Stock
Glatfelter
SupplierCustomer0,850,30-0,69-0,64-0,47-0,23
Eurofins Scientific Stock
Eurofins Scientific
SupplierCustomer0,84-0,050,55-0,34-0,120,73
Socket Mobile Stock
Socket Mobile
SupplierCustomer0,840,700,34-0,45-0,380,49
Macfarlane Group Stock
Macfarlane Group
SupplierCustomer0,820,31--0,50-0,39-
1
2
3
4
5
...
26

Most common questions regarding Johnson & Johnson

What values and corporate philosophy does Johnson & Johnson represent?

Johnson & Johnson is a renowned global healthcare company that upholds strong values and a clear corporate philosophy. With a commitment to improving the well-being of people worldwide, the company focuses on three fundamental principles: caring for the world, keeping customers at the center, and cherishing employees. Johnson & Johnson values integrity, innovation, diversity, and collaboration, consistently striving to deliver high-quality products and solutions. With a customer-centric approach, the company endeavors to create lasting relationships and enhance experiences. By fostering a supportive work environment and promoting professional growth, Johnson & Johnson ensures its employees play a vital role in achieving its mission.

In which countries and regions is Johnson & Johnson primarily present?

Johnson & Johnson is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered, and it operates in countries across North America, Europe, Asia Pacific, and Latin America. Some prominent regions where Johnson & Johnson operates include Canada, Germany, France, Japan, Australia, Brazil, and China. With its diverse portfolio of healthcare products and services, Johnson & Johnson continues to expand its presence globally, serving the healthcare needs of people in numerous countries and regions.

What significant milestones has the company Johnson & Johnson achieved?

Some significant milestones achieved by Johnson & Johnson include the development of innovative medical treatments and breakthrough pharmaceutical products. Throughout its history, the company has also played a crucial role in the advancement of healthcare technology and the improvement of patient care. Johnson & Johnson has consistently demonstrated its commitment to quality and safety, earning a reputation as a trusted global healthcare leader. With a strong focus on research and development, the company has introduced numerous life-saving and life-enhancing solutions to address a wide range of medical needs. Through its dedication to innovation and excellence, Johnson & Johnson continues to shape the future of healthcare.

What is the history and background of the company Johnson & Johnson?

Johnson & Johnson is a multinational healthcare company that was founded in 1886. It has a rich history and has become a leader in the pharmaceutical